The VLA-4 and VCAM-1 axis is also functional in HSCs and inhibiting this axis for therapeutic purposes in myeloma may cause unwelcome side effects; the same is also true for AMD3100 [69]. The gene discussed is VCAM1; the disease is plasma cell myeloma.